The European Commission (EC) has granted marketing authorisation for Johnson & Johnson's (J&J) Tremfya (guselkumab) to treat adults with moderately to severely active ulcerative colitis (UC) who have ...
The European Commission (EC) has granted marketing authorisation for Pfizer's anti-tissue factor pathway inhibitor (anti-TFPI), HYMPAVZI (marstacimab), to treat prophylaxis of bleeding incidents in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback